Market Indices
Sector Heatmap
CRVS — Corvus Pharmaceuticals, Inc.
NasdaqCorvus Pharmaceuticals, Inc.
- O
- 11.11
- H
- 11.11
- L
- 10.64
- V
- 1.35M
CRVS — Latest News & Headlines
9 StoriesCRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside Stocktwits
One drug is now in trials for four conditions, including a skin disease. - Stock Titan
One drug is now in trials for four conditions, including a skin disease. Stock Titan
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In? - Yahoo! Finance Canada
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In? Yahoo! Finance Canada
Trading the Move, Not the Narrative: (CRVS) Edition - Stock Traders Daily
Trading the Move, Not the Narrative: (CRVS) Edition Stock Traders Daily
CRVS Apr 2027 12.000 put (CRVS270416P00012000) Interactive Stock Chart - Yahoo Finance - Yahoo! Finance Canada
CRVS Apr 2027 12.000 put (CRVS270416P00012000) Interactive Stock Chart - Yahoo Finance Yahoo! Finance Canada
Corvus begins phase 1b trial of soquelitinib for skin disease By Investing.com - in.investing.com
Corvus begins phase 1b trial of soquelitinib for skin disease By Investing.com in.investing.com
CRVS270115C00011000 Interactive Stock Chart | CRVS Jan 2027 11.000 call Stock - Yahoo Finance
CRVS270115C00011000 Interactive Stock Chart | CRVS Jan 2027 11.000 call Stock Yahoo Finance
CRVS270416C00020000 Interactive Stock Chart | CRVS Apr 2027 20.000 call Stock - Yahoo! Finance Canada
CRVS270416C00020000 Interactive Stock Chart | CRVS Apr 2027 20.000 call Stock Yahoo! Finance Canada
Korsana Biosciences (KRSA) At $31.20 Leaves Valuation Questions On A Sharp 2026 Run - Yahoo Finance
Korsana Biosciences (KRSA) At $31.20 Leaves Valuation Questions On A Sharp 2026 Run Yahoo Finance